A Case Study : Stem Cell Therapy to Support Chronic Ulcerative Colitis and Gastrointestinal Inflammation

Case Overview

This case involves a 72-year-old woman from the United States who has struggled with chronic gastrointestinal inflammation and lower abdominal discomfort for several years, primarily driven by long-standing Ulcerative Colitis. This ongoing condition has severely affected her quality of life, daily comfort, appetite, and general energy levels. The persistent abdominal pain and recurrent disease flare-ups have made maintaining adequate nutrition and daily physical wellbeing increasingly challenging.

Despite her complex medical history, the patient has remained proactive in seeking medical care to manage her health and restore her vitality. She presented to the clinic seeking supportive regenerative solutions to help calm chronic systemic inflammation, improve gut environment stability, and enhance her overall quality of life.

Symptom Background and Previous Treatment History

The patient reported an approximate 7-year history of chronic gastrointestinal symptoms, including persistent abdominal discomfort, loss of appetite, and altered bowel habits. Medical records confirmed a known history of Ulcerative Colitis / Crohn’s disease, with periodic severe flare-ups. Notably, she experienced a major flare-up in June 2024 that required acute hospitalization. Diagnostic workups, including a colonoscopy, confirmed significant ulcerative inflammatory changes along the intestinal tract.

Her broader medical history includes a hospitalization in mid-February 2025 for a renal abscess, which was managed medically. Over the years, conventional conservative management and pharmaceutical interventions provided only temporary stabilization during acute exacerbations without halting long-term disease progression. Given the recurrent nature of her symptoms and their cumulative impact on her energy, nutritional status, and daily functioning, she sought an integrative approach incorporating cell-based supportive care.

Medical Report

The 2025 abdominal CT scan and laboratory evaluations reveal a combination of structural and systemic findings across several organ systems. Within the gastrointestinal tract, an irregular mass measuring approximately was identified in the lower right abdomen near the cecum, causing mild compression on adjacent small bowel loops, alongside a benign fatty lesion near the ileocecal valve, and scattered non-inflamed diverticula in the lower colon. Evaluation of the hepatobiliary system and spleen demonstrated mild enlargement of specific liver lobes suspicious for early cirrhotic changes, mild bile duct dilatation, and marked atrophy of the spleen. Additionally, examination of the kidneys and pelvic organs showed multiple small fluid-filled cysts across both kidneys as well as two uterine fibroids. Normal kidney function markers (BUN and Creatinine) confirmed safe clearance of the contrast agent used during imaging.

Overall, these findings indicate that the patient’s health symptoms do not stem from a single isolated issue, but rather from a complex combination of chronic autoimmune bowel inflammation, impaired mucosal barrier integrity, localized soft-tissue compression, and systemic inflammatory strain. This multifactorial presentation provides a strong clinical rationale for utilizing cellular signaling therapy to help regulate immune balance, reduce the overall inflammatory burden, and support tissue recovery.

Condition & Stem Cell Therapy

Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSCs) are widely studied in regenerative gastroenterology for their capacity to release potent paracrine factors including anti-inflammatory cytokines, growth factors, and extracellular vesicles that modulate immune responses and facilitate tissue repair mechanisms.

For chronic autoimmune gastrointestinal conditions such as Ulcerative Colitis, stem cell therapy should not be presented as a cure or as a treatment that physically removes structural masses or lesions. Rather, it serves as a supportive intervention designed to regulate the biological environment within inflamed intestinal tissues. Key proposed mechanisms include:

Modulating Intestinal Inflammation: Helping downregulate excessive pro-inflammatory cytokine pathways driving mucosal breakdown.

Supporting Immune System Balance: Facilitating immune cell regulation to decrease autoimmune reactivity against gut tissue.

Promoting Mucosal Microenvironment Healing: Supporting paracrine signaling to encourage epithelial tissue repair and intestinal barrier recovery.

Lowering Systemic Inflammatory Burden: Providing systemic anti-inflammatory signaling that benefits multi-organ health, particularly relevant for patients with co-existing inflammatory issues.

Following thorough clinical consultation including clear discussion regarding the CT scan findings and the presence of the RLQ mass the patient provided informed consent to proceed with an individualized UC-MSC protocol integrated with IV nutrient support.

Treatment in 2024

In 2024, the patient initiated her first cellular care phase to address chronic systemic inflammation and gut mucosal stress:

IV UC-MSCs: Approximately 50 million cells administered via intravenous infusion.

This initial protocol was designed to provide broad immunomodulatory support, reduce systemic inflammatory cytokines, and stabilize her baseline gut function.

Treatment in 2025

In 2025, the patient received integrative metabolic and cellular therapies to support recovery and cellular energy:

Systemic Support: Vega Vitamin IV infusion combined with NAD+.

During this period, she was also closely monitored and managed for an intercurrent renal abscess hospitalization, ensuring overall systemic stability before further cell therapy.

Treatment in 2025

In 2025, following re-evaluation and detailed informed consent review regarding her abdominal CT findings, the patient underwent an additional systemic cell protocol:

IV UC-MSCs: Approximately 50 million cells administered intravenously.

Supportive IV Therapy: Vega Vitamin IV infusion.

This phase aimed to reinforce immunomodulation, support ongoing gastrointestinal lining recovery, and assist overall physical stamina.

Patient-Reported Outcome and Feedback

Following her treatment courses, the patient reported steady, meaningful improvements in her overall quality of life and daily comfort. Key patient-reported outcomes included:

Reduction in Abdominal Discomfort: Significant decrease in chronic lower abdominal pain and cramping episodes.

Improved Appetite & Digestion: Gradual recovery of appetite and better tolerance of daily meals.

Stabilized Energy Levels: Noticeable improvement in daily vitality and reduced systemic fatigue following NAD+ and IV cell infusions.

Enhanced Wellbeing: Greater confidence in performing daily activities without constant concern over gastrointestinal distress.

Note: These findings represent individual self-reported observations. Clinical responses to regenerative therapies vary between individuals based on overall health, underlying disease complexity, and adherence to supportive care.

Doctor’s Perspective

From a clinical standpoint, managing chronic gastrointestinal conditions like Ulcerative Colitis requires a holistic, multi-dimensional assessment beyond surface symptoms. In this case, the patient presented with significant structural and mucosal inflammation alongside co-existing findings such as an RLQ abdominal mass, hepatic alterations, and a history of renal infection.

Key clinical takeaways from this case include:

Multifactorial Assessment: Autoimmune gut pain involves complex interactions between mucosal barrier breakdown, immune dysregulation, and systemic cytokine signaling.

Careful Risk Mitigation & Consent: Incidental structural findings (such as abdominal masses) must be thoroughly evaluated and discussed transparently with the patient prior to cell therapy.

Comprehensive Supportive Protocols: Combining UC-MSCs with targeted metabolic support (such as NAD+ and micronutrient IVs) enhances overall cellular resilience and recovery.

Realistic Expectations: Stem cell therapy serves as an integrative support tool to promote inflammatory balance and mucosal healing, rather than an immediate cure or surgical substitute.

Conclusion

This case demonstrates an individualized regenerative care approach for a 72-year-old patient managing chronic Ulcerative Colitis and multi-organ medical considerations. Through structured cycles of IV Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSCs), NAD+, and targeted IV vitamin therapy, the patient achieved noticeable improvements in abdominal comfort, appetite, energy, and overall quality of life.

This case emphasizes the necessity of careful diagnostic evaluation, open communication regarding risk-benefit profiles, and a balanced clinical approach. Systemic cell therapy offers a valuable supportive option in regenerative gastroenterology when delivered responsibly with a primary focus on patient safety, functional outcomes, and long-term health.

A Case Study Stem Cell Therapy to Support Chronic Ulcerative Colitis and Gastrointestinal Inflammation